Literature DB >> 8880017

Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease.

M Caputo1, G Mantini, I Floriani, M Ciceri, A Noseda, L Bonomo.   

Abstract

In order to evaluate the relationship between the presence of atherosclerotic disease, documented by angiography, and the fibrinolytic profile, 262 consecutive patients affected by coronary (n = 90), epiaortic (n = 60) and peripheral (n = 104) artery disease have been included in the study. Twenty-two healthy subjects were used as controls for laboratory parameters determination. All patients were classified on the basis of the presence (S+) or absence (S-) of clinically significant stenosis, according to specific scoring systems. Lipoprotein(a), plasminogen activator inhibitor (PAI-1), tissue plasminogen activator (t-PA) and the PAI-1/t-PA ratio were significantly lower in controls than in coronary, epiaortic and peripheral artery disease patients. However, the levels of these parameters were not statistically different between S+ and S- subjects. These results confirm the association between lipoprotein(a), PAI-1 and t-PA levels and the presence of atherosclerotic disease independently of the arterial districts considered, while they do not appear to be directly linked to the severity of the morphological disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880017     DOI: 10.1093/oxfordjournals.eurheartj.a015066

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  4 in total

1.  Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome.

Authors:  Francesco Imperatore; Salvatore Cuzzocrea; Domenico De Lucia; Marcella Sessa; Barbara Rinaldi; Annalisa Capuano; Giovanni Liguori; Amelia Filippelli; Francesco Rossi
Journal:  Intensive Care Med       Date:  2006-09-15       Impact factor: 17.440

2.  Fibrinolytic variables in postmenopausal women with unstable coronary artery disease.

Authors:  N E Nielsen; E Logander; E Swahn
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

Review 3.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

4.  Risk factors for coronary artery sclerosis in patients with diabetes.

Authors:  Akihiro Nishiyama; Chihiro Shikata; Nobuaki Kimura; Akio Imanishi; Noriyuki Hirai; Makoto Ohta; Nobuakira Takeda
Journal:  Exp Clin Cardiol       Date:  2005
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.